Chang, Ching-Yuan
Jones, Bobby L.
Hincapie-Castillo, Juan M.
Park, Haesuk
Heldermon, Coy D.
Diaby, Vakaramoko
Wilson, Debbie L.
Lo-Ciganic, Wei-Hsuan https://orcid.org/0000-0001-6590-4770
Article History
Received: 3 March 2023
Accepted: 29 November 2023
First Online: 8 January 2024
Declarations
:
: Dr Lo-Ciganic reported receiving grants from the National Institute on Drug Abuse, the National Institute on Aging, the National Institute of Mental Health, Merck Sharp & Dohme, Bristol Myers Squibb, the Richard King Mellon Foundation at the University of Pittsburgh, the Clinical and Translational Science Institute of the University of Florida, the Pharmaceutical Research and Manufacturers of America Foundation, and the US Department of Veterans Affairs outside the submitted work; and having a patent pending for U1195.70174US00. Dr Park reported receiving grants from Bristol-Myers Squibb/Pfizer Alliance American Thrombosis Investigator Initiated Research Program outside the submitted work. Dr Hincapie-Castillo reported receiving grants from Merck & Co outside the submitted work. Ms Wilson reported receiving grants from the National Institute on Drug Abuse, the National Institute on Aging, Merck Sharp & Dohme, and Bristol Myers Squibb outside the submitted work; and serving as an editorial board member for the <i>Journal of Pharmacy Technology</i>. Dr Chang's contributions to this manuscript were made while at the University of Florida College of Pharmacy. Dr Chang is currently employed by Vertex Pharmaceuticals, Inc. Vertex did not fund or have any involvement in this study or publication. Dr Diaby is currently employed by Otsuka, Inc. Otsuka did not fund or have any involvement in this study or publication. No other disclosures were reported.